Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2008.

Vanda reported research and development (R&D) expenses in the third quarter of 2008 of $3.8 million, compared to $5.5 million in the second quarter of 2008 and $13.9 million in the third quarter of 2007. The decrease in R&D expenses in the third quarter of 2008 relative to the second quarter of 2008 is primarily attributable to lower costs in the Phase III tasimelteon (VEC-162) chronic primary insomnia clinical trial for which Vanda announced top-line results in June of 2008. The decrease in R&D expenses in the third quarter of 2008 relative to the third quarter of 2007 is attributable to lower clinical trial costs in 2008 compared to costs from trials conducted in 2007, and the $5.0 million milestone charge recorded in the third quarter of 2007 resulting from the submission of the New Drug Application (NDA) for iloperidone.

Net loss was $10.9 million for the third quarter of 2008, compared to $13.5 million for the second quarter of 2008 and $21.9 million for the third quarter of 2007. Net loss per common share for the third quarter of 2008 was $0.41, compared to $0.51 for the second quarter of 2008 and $0.82 for the third quarter of 2007.

As of September 30, 2008, Vanda's cash, cash equivalents, and marketable securities totaled approximately $51.7 million. As of September 30, 2008, Vanda had a total of approximately 26.7 million shares of common stock outstanding.

OPERATIO
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... Study on 3D Cell Culture: Asia ... Persistence Market Research, the global 3D cell culture market was valued ... to expand at a CAGR of 29.1% to account ... Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D ...
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
Breaking Biology Technology:Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... PARK, N.C., June 14, 2011 Bayer CropScience ( ... top innovative crop science companies in the areas of ... announced the release of a video featuring the organization,s ... award-winning program, Making Science Make Sense (MSMS) . ...
... PAREXEL International Corporation (NASDAQ: PRXL ... Wells Fargo Healthcare Conference in Boston, MA.  James Winschel, Sr. ... presentation on PAREXEL at 2:00 p.m. ET on Wednesday, June ... will be available through the "Investors" section of ...
... industry delivered solid top- and bottom-line growth in 2010, with ... a row. Yet funding for research and ... firms in the sector, which tend to be pre-commercial stage ... development. This has placed new pressure on the traditional biotech ...
Cached Biology Technology:Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center 2Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center 3Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center 4Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center 5PAREXEL International to Present at Wells Fargo Healthcare Conference 2Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 2Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 3Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 4Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 5Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 6
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... on the growing mobile commerce market announces a revised version of ... week. The commercial will air on CNBC in New ... Angeles and San Francisco metro ... commercial focuses on Wocket,s ability to replace all the cards in ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... This release is available in French . ... in collaboration with Nova Scotia Agricultural College, have discovered what ... double the lifespan of Christmas trees in homes. The authors ... journal Trees . The researchers have identified a ...
... is not just a feature unique to humans and ... revealed that also brown trout have individual characters and ... Department of Zoology at the University of Gothenburg has ... from watercourses on the west coast of Sweden. ...
... of Change, literally took 100 years to write. The first ... It was repeated from 1956-1958 and a technical book was ... that first survey was approaching, ornithologists Mike Ward, Jeff Walk, ... to do it again and write a book, this time ...
Cached Biology News:Researchers discover a way to delay Christmas tree needle loss 2New book on 100 years of Illinois birds 2New book on 100 years of Illinois birds 3New book on 100 years of Illinois birds 4
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Human Cystatin F MAb (Clone 292103)...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
... an inhibitor of caspase-3/7 ... of inhibitor required to ... be determined empirically for ... inhibitor is sufficient to ...
Biology Products: